Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.

In this study, chemical feature based pharmacophore models of type I and type II kinase inhibitors of Tie2 have been developed with the aid of HipHop and HypoRefine modules within Catalyst program package. The best HipHop pharmacophore model Hypo1_I for type I kinase inhibitors contains one hydrogen-bond acceptor, one hydrogen-bond donor, one general hydrophobic, one hydrophobic aromatic, and one ring aromatic feature. And the best HypoRefine model Hypo1_II for type II kinase inhibitors, which was characterized by the best correlation coefficient (0.976032) and the lowest RMSD (0.74204), consists of two hydrogen-bond donors, one hydrophobic aromatic, and two general hydrophobic features, as well as two excluded volumes. These pharmacophore models have been validated by using either or both test set and cross validation methods, which shows that both the Hypo1_I and Hypo1_II have a good predictive ability. The space arrangements of the pharmacophore features in Hypo1_II are consistent with the locations of the three portions making up a typical type II kinase inhibitor, namely, the portion occupying the ATP binding region (ATP-binding-region portion, AP), that occupying the hydrophobic region (hydrophobic-region portion, HP), and that linking AP and HP (bridge portion, BP). Our study also reveals that the ATP-binding-region portion of the type II kinase inhibitors plays an important role to the bioactivity of the type II kinase inhibitors. Structural modifications on this portion should be helpful to further improve the inhibitory potency of type II kinase inhibitors.

[1]  M. Dewhirst,et al.  Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[2]  Allison L. Zulli,et al.  Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[3]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[4]  H. Huland,et al.  The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. , 2000, Anticancer research.

[5]  Ralph Mazitschek,et al.  Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. , 2004, Current opinion in chemical biology.

[6]  Allison L. Zulli,et al.  Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases. , 2008, Bioorganic & medicinal chemistry letters.

[7]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[8]  M. Webb,et al.  Identification and characterization of small‐molecule inhibitors of Tie2 kinase , 2008, FEBS letters.

[9]  Taebo Sim,et al.  A general strategy for creating "inactive-conformation" abl inhibitors. , 2006, Chemistry & biology.

[10]  S. Leung,et al.  The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. , 2000, Lung cancer.

[11]  Qian Huang,et al.  The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies , 2007, Chemical biology & drug design.

[12]  Yutaka Maeda,et al.  Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[13]  J. Adams,et al.  Pyridinylimidazole inhibitors of Tie2 kinase. , 2007, Bioorganic & medicinal chemistry letters.

[14]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[16]  Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. , 2006, Bioorganic & medicinal chemistry letters.

[17]  S. Vadivelan,et al.  Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors , 2007, J. Chem. Inf. Model..

[18]  F. Bach,et al.  Angiopoietins in malignancy. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[20]  Qian Huang,et al.  Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[21]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[22]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[23]  C. Bennett,et al.  The value of innovation: the economics of targeted drugs for cancer , 2007, Targeted Oncology.

[24]  P. A. Harris,et al.  Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. , 2007, Journal of medicinal chemistry.

[25]  T. Acker,et al.  Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor‐2 dominant‐negative receptor mutants , 2001, International journal of cancer.

[26]  T. Ganesan,et al.  Tyrosine kinase inhibitors in cancer therapy. , 2004, Clinical biochemistry.

[27]  David Powers,et al.  Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. , 2007, Journal of medicinal chemistry.

[28]  Richard Kendall,et al.  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. , 2007, Journal of medicinal chemistry.

[29]  K. Tsai,et al.  Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. , 2005, Biochemical and biophysical research communications.